Drug Evaluation

Mayo College of Medicine, Multidisciplinary Breast Clinic, Mayo Clinic Florida, FL, USA.

Email the corresponding author at morenoaspitia.alvaro@mayo.edu

Published Online:13 May 2010https://doi.org/10.2217/fon.10.41

Abstract

Breast carcinoma remains the most common malignancy of women around the world, and despite the advances in the early diagnosis and adjuvant treatment of this disease, many women still relapse with metastatic breast cancer. There is therefore an urgent need for the development and testing of novel agents targeting pathways thought to be involved in the pathogenesis of breast cancer. Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell proliferation, cell growth, prevention of apoptosis, tumor invasion and neo-angiogenesis. Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of malignant breast cancer cells. This article reviews previous experiences and current and future development strategies of sorafenib in breast cancer.

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

1 Althuis MD, Dozier JD, Anderson WF et al.: Global trends in breast cancer incidence and mortality 1973–1997. Int. J. Epidemiol.34,405–412 (2005).Crossref, Medline, Google Scholar
2 Marshall CJ: Raf gets it together. Nature383,127–128 (1996).Crossref, Medline, CAS, Google Scholar
3 Davies H, Bignell GR, Cox C et al.: Mutations of the BRAF gene in human cancer. Nature417,949–954 (2002).Crossref, Medline, CAS, Google Scholar
4 Sivaraman VS, Wang H, Nuovo GJ, Malbon CC: Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest.99,1478–1483 (1997).Crossref, Medline, CAS, Google Scholar
5 Kolch W. Meaningful relationships the regulation of the Ras/Raf/Mek-ERK pathway by protein interactions. Biochem. J.351,289–305 (2000).Crossref, Medline, CAS, Google Scholar
6 Takahashi T, Ueno H, Shibuya M: VEGF activates protein kinase C-dependent, but Ras independent Raf–MEK–MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene18,2221–2230 (1999).Crossref, Medline, CAS, Google Scholar
7 Adjei AA: Signal transduction pathway targets for anticancer drug discovery. Curr. Pharm. Des.6,361–378 (2000).Crossref, Medline, CAS, Google Scholar
8 Lee JT Jr, McCubrey JA: The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention. Leukemia16,486–507 (2002).Crossref, Medline, CAS, Google Scholar
9 Franklin RA, McCubrey JA: Kinases positive and negative regulators of apoptosis. Leukemia14,2019–2034 (2000).Crossref, Medline, CAS, Google Scholar
10 Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell61,203–212 (1990).Crossref, Medline, CAS, Google Scholar
11 Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang F, McCubrey JA: Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-dependent tumors. Pharm. Ther.88,229–279 (2000).Crossref, Medline, CAS, Google Scholar
12 Samuels ML, Weber MJ, Bishop JM, McMahon M: Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human Raf-1 protein kinase. Mol. Cell. Biol.13,6241–6252 (1993).Medline, CAS, Google Scholar
13 Folkman J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.285,1182–1186 (1971).Crossref, Medline, CAS, Google Scholar
14 Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat. Med.9,669–676 (2003).Crossref, Medline, CAS, Google Scholar
15 Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist9(Suppl. 1),2–10 (2004).Crossref, Medline, CAS, Google Scholar
16 Dvorak HF: Angiogenesis: update 2005. J. Thromb. Haemost.3,1835–1842 (2005).Crossref, Medline, CAS, Google Scholar
17 Underiner TL, Ruggeri B, Gingrich DE: Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as antiangiogenic agents in cancer therapy. Curr. Med. Chem.11,731–745 (2004).Crossref, Medline, CAS, Google Scholar
18 Avastin^®, package insert. Genentech, CA, USA (2009).Google Scholar
19 Miller K, Wang M, Gralow J et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for MBC. N. Engl. J. Med.357(26),2666–2667 (2007).Crossref, Medline, CAS, Google Scholar
20 Robert NJ, Dieras V, Glaspy J et al.: RIBBON-1: randomized, double-blind, placebo controlled, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or MBC. Presented at: 2009 ASCO Annual Meeting. Chicago, IL, USA, 30 May–2 June (2009) (Abstract 1005).Google Scholar
21 Ro J, Bresser J, Ro JY et al.: SIS/PDGF-B expression in benign and malignant human breast lesions. Oncogene4(3),351–354 (1989).Medline, CAS, Google Scholar
22 Ginsburg E, Vonderhaar BK: Stimulation of growth of human breast cancer cells (T47D) by platelet derived growth factor. Cancer Lett.58(1–2),137–144 (1991). Erratum in: Cancer Lett.59(3),267 (1991).Crossref, Medline, CAS, Google Scholar
23 Ariad S, Seymour L, Bezwoda WR: Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res. Treat.20(1),11–17 (1991).Crossref, Medline, CAS, Google Scholar
24 Coltrera MD, Wang J, Porter PL, Gown AM: Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor β subunit in human breast tissue and breast carcinoma. Cancer Res.55(12),2703–2708 (1995).Medline, CAS, Google Scholar
25 Bhardwaj B, Klassen J, Cossette N et al.: Localization of platelet-derived growth factor β receptor expression in the periepithelial stroma of human breast carcinoma. Clin. Cancer Res.2(4),773–782 (1996).Medline, CAS, Google Scholar
26 English JM, Cobb MH: Pharmacological inhibitors of MAPK pathways. Trends Pharmacol. Sci.23,40–45 (2002).Crossref, Medline, CAS, Google Scholar
27 Lee JT, McCubrey JA: Targeting the Raf kinase cascade in cancer therapy – novel molecular targets and therapeutic strategies. Exp. Opin.6,1–20 (2002).Google Scholar
28 Gasparini G, Longo R, Torino F, Morabito A: Therapy of breast cancer with molecular targeting agents. Ann. Oncol.16(Suppl. 4),IV28–IV36 (2005).Crossref, Medline, Google Scholar
29 Lin NU, Winer EP: New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res.6(5),204–210 (2004).Crossref, Medline, CAS, Google Scholar
30 Kaklamani V, O’Regan RM: New targeted therapies in breast cancer. Semin. Oncol.31(2 Suppl. 4),20–25 (2004).Crossref, Medline, CAS, Google Scholar
31 Rexer BN, Ghosh R, Arteaga CL: Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clin. Cancer Res.15(14),4518–4520 (2009).Crossref, Medline, CAS, Google Scholar
32 Fischgräbe J, Wülfing P: Targeted therapies in breast cancer: established drugs and recent developments. Curr. Clin. Pharmacol.3(2),85–98 (2008).Crossref, Medline, Google Scholar
33 Johnston SRD: Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists. Int. J. Gynecol. Cancer16(Suppl. 2),543–548 (2006).Crossref, Medline, Google Scholar
34 Nexavar^®, package insert. Onyx Pharmaceutical, CA, USA (2005).Google Scholar
35 Strumberg D, Richly H, Hilger RA et al.: Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J. Clin. Oncol.23,965–972 (2005).Crossref, Medline, CAS, Google Scholar
36 Cobleigh MA, Langmuir VK, Sledge GW et al.: A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol.30(Suppl. 16),117–124 (2003).Crossref, Medline, CAS, Google Scholar
37 Wilhelm S, Carter C, Lynch M et al.: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov.5,835–844 (2006).Crossref, Medline, CAS, Google Scholar
38 Wilhelm SM, Carter C, Tang L et al.: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64,7099–7109 (2004).Crossref, Medline, CAS, Google Scholar
39 Wilhelm S, Chien DS: BAY 43–9006: preclinical data. Curr. Pharm. Des.8,2255–2257 (2002).Crossref, Medline, CAS, Google Scholar
40 Lierman E, Lahortiga I, Van Miegroet H et al.: The ability of sorafenib to inhibit oncogenic PDGFRβ and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica92,27–34 (2007).Crossref, Medline, CAS, Google Scholar
41 Moore M, Hirte HW, Siu L et al.: Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43– 9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann. Oncol.16,1688–1694 (2005).Crossref, Medline, CAS, Google Scholar
42 Hotte SJ, Hirte HW: BAY 43–9006: early clinical data in patients with advanced solid malignancies. Curr. Pharm. Des.8,99–110 (2002).Crossref, Medline, Google Scholar
43 Carlomagno F, Anaganti S, Guida T et al.: BAY 43–9006 inhibition of oncogenic RET mutants. J. Natl Cancer Inst.98,326–334 (2006).Crossref, Medline, CAS, Google Scholar
44 Yu C, Bruzek LM, Kaufmann SH et al.: The raf kinase inhibitor BAY 43– 9006 accelerates Mcl-1 degradation and regulates pro-apoptotic function. Clin. Cancer Res.46,6155 (2005).Google Scholar
45 Richly H, Kupsch P, Passage K et al.: Results of a Phase I trial of BAY 43–9006 in combination with doxorubicin in patients with refractory solid tumors. J. Clin. Oncol.23,207 (2004) (Abstract).Google Scholar
46 Azad NS, Annunziata C, Barrett T et al.: Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: clinical and translational results. J. Clin. Oncol.25,3542 (2007) (Abstract).Crossref, Google Scholar
47 Escudier B, Eisen T, Stadler WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356,125–134, (2007).▪▪ Demonstrates that sorafenib as a single agent has significant activity in metastatic renal cell carcinoma.Crossref, Medline, CAS, Google Scholar
48 Llovet J, Ricci S, Mazzaferro V et al.: Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359(4),378–390 (2008).▪▪ Demonstrates that sorafenib as a single agent has significant activity in metastatic hepatocellular carcinoma.Crossref, Medline, CAS, Google Scholar
49 Moreno-Aspitia A, Morton RF, Hillman DW et al.: Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracycline or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J. Clinic. Oncol.27(1),11–15 (2009).▪▪ Demonstrates that sorafenib as a single agent has low activity in metastatic breast cancer.Crossref, Medline, CAS, Google Scholar
50 Bianchi G, Loibl S, Zamagni C et al.: Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs20(7),616–624 (2009).▪▪ Corroborates that sorafenib as single agent has low activity in metastatic breast cancer.Crossref, Medline, CAS, Google Scholar
51 Kober F, Hermann M, Handler A et al.: Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. J. Clin. Oncol.25, 617. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June (2007) (Abstract 14065).Crossref, Google Scholar
52 Adjei AA, Molina JR, Hillman SL et al.: A front-line window of opportunity Phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study. J. Clin. Oncol.25, 396. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June (2007) (Abstract 7547).Crossref, Medline, Google Scholar
53 Keohan M, D’Adamo D, Qin L et al.: Analysis of toxicity in a Phase II study of sorafenib in soft tissue sarcoma (STS). J. Clin. Oncol.25, 560. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June (2007) (Abstract 10061).Crossref, Google Scholar
54 Agarwala SS, Keilholz U, Hogg D et al.: Randomized Phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. J. Clin. Oncol.25, 474. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1–5 June (2007) (Abstract 8510).Crossref, Medline, Google Scholar
55 Elser C, Siu LL, Winquist E et al.: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J. Clin. Oncol.25,3766–3773 (2007).Crossref, Medline, CAS, Google Scholar
56 Baselga J, Gianni L, Gradishar WJ et al.: Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program. Presented at: 2009 ASCO Annual Meeting. Chicago, IL, USA, 4–8 June (2009).Google Scholar
57 Gradishar WJ, Kaklamani V, Prasad Sahoo T et al.: A double-blind, randomized, placebo-controlled, Phase IIb study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC). Presented at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December (2009) (Abstract 44).▪ Demonstrates that sorafenib in combination with paclitaxel is active but associated with significant toxicity and why some of these toxicities may apply only to some regions of the world.Google Scholar
58 Baselga J; Grupo Español de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos, Roché H et al.: SOLTI-0701: A multinational double-blind, randomized Phase IIB study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Presented at: ECCO 15 and 34th ESMO Multidisciplinary Congress. Berlin, Germany, 20–24 September (2009) (Abstract 3LBA). Updated at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December (2009) (Abstract 45).▪ Demonstrates significant activity of sorafenib in combination with capecitabine.Google Scholar
59 Bonelli MA, Fumarola C, Alfieri RR et al.: Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res. Treat. (2010) (Epub ahead of print).Medline, Google Scholar
60 Tan A, Reiss M, Wong S et al.: Letrozole and sorafenib as first-line therapy in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC): preliminary results. Presented at: 2009 ASCO Breast Cancer Symposium. San Francisco, CA, USA, 8–10 October (2009) (Abstract 256).Google Scholar
61 Isaacs C, Wilkinson M, Liu MC et al.: Phase I/II study of sorafenib with anastrozole to overcome resistance to aromatase inhibitors (AIs) in patients with hormone receptor positive (ER/PR+) AI resistant metastatic breast cancer (MBC). Presented at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December (2009) (Abstract 3090).Google Scholar
62 Azad NS, Posadas EM, Kwitkowski VE et al.: Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol.26,3709–3714 (2008).Crossref, Medline, CAS, Google Scholar
63 Spigel DR, Molthrop D, Peacock N et al.: A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel plus sorafenib in women with node positive or high-risk breast cancer. Presented at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December (2009) (Abstract 2110).Google Scholar
64 Miller KD, Chap LI, Holmes FA et al.: Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol.23,792–799 (2005).Crossref, Medline, CAS, Google Scholar
65 Brufski A, Bondarenko IN, Smirnov S et al.: RIBBON-2: a randomized, double-blind, placebo-controlled, Phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Presented at: 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 9–13 December (2009) (Abstract 42).Google Scholar
66 Traina TA, Theodoulou M, Feigin K et al.: Phase I study of a novel capecitabine schedule based on the Norton–Simon mathematical model in patients with metastatic breast cancer. J. Clin. Oncol.26(11),1797–1802 (2008).Crossref, Medline, CAS, Google Scholar
101 US NIH: Clinicaltrials.gov http://clinicaltrials.govGoogle Scholar
102 NCT00632541: Hoosier Oncology Group BRE06–109. A Phase II of Sorafenib and bevacizumab in Metastatic Breast Cancer http://clinicaltrials.gov/ct2/results?term_NCT00632541 (Accessed January 2010)Google Scholar
103 NCT00825734: Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer http://clinicaltrials.gov/ct2/results?term_NCT00825734 (Accessed December 2009)Google Scholar
104 NCT00828074: Phase I/II Trial of Sorafenib Tosylate and Vinorelbine Ditartrate in Women with Stage IV Adenocarcinoma of the Breast http://clinicaltrials.gov/ct2/results?term_NCT00828074 (Accessed December 2009)Google Scholar
105 NCT00764972: Phase IB/II Trial of Sorafenib and Vinorelbine as First Line Treatment in Metastatic Breast Cancer. http://clinicaltrials.gov/ct2/results?term_NCT00764972 (Accessed December 2009)Google Scholar
106 NCT00493636: A Double-Blind, Randomized Phase IIb Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy http://clinicaltrials.gov/ct2/results?term_NCT00493636 (Accessed December 2009)Google Scholar
107 NCT00622466: Phase II Study of Sorafenib Tosylate and Paclitaxel in Patients with Metastatic HER2-Negative Breast Cancer http://clinicaltrials.gov/ct2/results?term_NCT00622466 (Accessed December 2009)Google Scholar
108 NCT00499525: Phase II Study of Paclitaxel With Versus Without Sorafenib Tosylate in Patients with Locally Recurrent or Metastatic Breast Cancer http://clinicaltrials.gov/ct2/results?term_NCT00499525 (Accessed December 2009)Google Scholar
109 NCT00722072: Sorafenib and Fulvestrant in Treating Patients with Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy http://clinicaltrials.gov/ct2/results?term_NCT00722072 (Accessed December 2009)Google Scholar
110 NCT00525161: Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients with Advanced Breast Cancer http://clinicaltrials.gov/ct2/results?term_NCT00525161 (Accessed December 2009)Google Scholar
111 NCT00217399: Phase I/II Trial of Sorafenib in Combination with Anastrozole in Post-Menopausal Women with Estrogen Receptor and/or Progesterone Receptor Positive Metastatic Breast Cancer http://clinicaltrials.gov/ct2/results?term_NCT00217399 (Accessed December 2009)Google Scholar
112 NCT00634634: Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone Receptor Positive Breast Cancer. http://clinicaltrials.gov/ct2/results?term_NCT00634634 (Accessed December 2009)Google Scholar
113 NCT00433511: Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer http://clinicaltrials.gov/ct2/results?term_NCT00433511 (Accessed December 2009)Google Scholar

Vol. 6, No. 5

Metrics

Downloaded 348 times

History

Published online 13 May 2010

Published in print May 2010

Information

Keywords

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Clinical overview of sorafenib in breast cancer

Abstract

Bibliography